Strategies of multi-objective optimization in drug discovery and development

Expert Opinion on Drug Discovery

Volumn 6, Issue 9, 2011, Pages 871-884

  Nicolotti, Orazio ^a   Giangreco, Ilenia ^a   Introcaso, Antonellina ^a   Leonetti, Francesco ^a   Stefanachi, Angela ^a   Carotti, Angelo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Chemoinformatics; Multi criterion optimization; Multi objective evolutionary algorithm; Multi objective optimization

Indexed keywords

DRUG;

DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; MOLECULAR DOCKING; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

EID: 80052071915     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2011.588696     Document Type: Review

References (82)

1. Greer J, Erickson JW, Baldwin JJ, Varney MD. Application of the three-dimensional structures of protein target molecules in structure-based drug design. J Med Chem 1994;37:1035-54 (Pubitemid 24145364)
2. Traxler P, Bold G, Buchdunger E, et al. Tyrosine kinase inhibitors: from rational design to clinical trials. Med Res Rev 2001;6:499-512 (Pubitemid 32959239)
3. Silverman RA. The organic chemistry of drug design and drug action. Elsevier Academic Press, Amsterdam; 2004
4. Marnett LJ, Kalgutkar AS. Design of selective inhibitors of cyclooxygenase-2 as nonulcerogenic anti-inflammatory agents. Curr Opin Chem Biol 1998;2:482-90 (Pubitemid 128645701)
5. Matthews T, Salgo M, Greenberg M, et al. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat Rev Drug Discov 2004;3:215-25 (Pubitemid 38379988)
6. Schames JR, Henchman RH, Siegel JS, et al. Discovery of a novel binding trench in HIV integrase. J Med Chem 2004;47:1879-81 (Pubitemid 38453905)
7. van de Waterbeemd H, Gifford E. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov 2003;2:192-204 (Pubitemid 37361664)
8. Nicolotti O, Gillet VJ, Fleming PJ, Green DVS. Multiobjective optimization in quantitative structure-activity relationships: deriving accurate and interpretable QSARs. J Med Chem 2002;45:5069-80 (Pubitemid 35278703)
9. Anisseh M, Yusuff RM. A fuzzy group decision making model for multiple criteria based on Borda count. Int J Phys Sci 2011;6:425-33
10. Reilly B. Social choice in the South Seas: electoral innovation and the Borda count in the Pacific Island Countries. Int Pol Sci Rev 2002;23:355-72
11. Chuu SJ. Group decision-making model using fuzzy multiple attributes analysis for the evaluation of advanced manufacturing technology. Fuzzy Sets Syst 2009;160:586-602
12. Nicolaou CA, Brown N, Pattichis CS. Molecular optimization using computational multi-objective methods. Curr Opin Drug Discov Devel 2007;10:316-24 (Pubitemid 46800225)
13. Van Veldhuizen DA, Lamont GB. Multiobjective evolutionary algorithms: analyzing the state-of-the-art. Evol Comput 2000;8:125-47
14. Goldreich O. Computational complexity: a conceptual perspective. CUP, Cambridge; 2008
15. Gillet VJ, Willett P, Bradshaw J, Green DVS. Selecting combinatorial libraries to optimize diversity and physical properties. J Chem Inf Comput Sci 1999;39:169-77 (Pubitemid 129676573)
16. Brown F. Editorial opinion: chemoinformatics-a ten year update. Curr Opin Drug Discov Devel 2005;8:298-302 (Pubitemid 40593423)
17. DeSimone RW, Currie KS, Mitchell SA, et al. Privileged structures: applications in drug discovery. Comb Chem High Throughput Screen 2004;7:473-94
18. Evans BE, Rittle KE, Bock MG, et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 1988;31:2235-46 (Pubitemid 19001640)
19. Boolell M, Allen MJ, Ballard SA, et al. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996;8:47-52
20. Welsch ME, Snyder SA, Stockwell BR. Privileged scaffolds for library design and drug discovery. Curr Opin Chem Biol 2010;14:1-15
21. Handschuh S, Wagener M, Gasteiger J. Superposition of three-dimensional chemical structures allowing for conformational flexibility by a hybrid method. J Chem Inf Comput Sci 1998;38:220-32 (Pubitemid 128591239)
22. Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 2004;9:641-51 (Pubitemid 38981718)
23. Jones G, Willett P, Glen RC. A genetic algorithm for flexible molecular overlay and pharmacophore elucidation. J Comput Aided Mol Des 1995;9:532-49
24. Jones G. GAPE: an improved genetic algorithm for pharmacophore elucidation. J Chem Inf Model 2010;50:2001-18
25. Gardiner EJ, Cosgrove DA, Taylor R, Gillet VJ. Multiobjective optimization of pharmacophore hypotheses: bias toward low-energy conformations. J Chem Inf Model 2009;49:2761-73
26. Cottrell SJ, Gillet VJ, Taylor R. Incorporating partial matches within multi-objective pharmacophore identification. J Comput Aided Mol Des 2006;20:735-49 (Pubitemid 46476943)
27. Clark RD, Abrahamian E. Using a staged multi-objective optimization approach to find selective pharmacophore models. J Comput Aided Mol Des 2009;23:765-71
28. Caballero J. 3D-QSAR (CoMFA and CoMSIA) and pharmacophore (GALAHAD) studies on the differential inhibition of aldose reductase by flavonoid compounds. J Mol Graph Model 2010;29:363-71
29. Hansch C, Maloney PP, Fujita T, Muir RM. Correlation of biological activity of phenoxyacetic acids with Hammett substituent constants and partition coefficients. Nature 1962;194:178-90
30. Liu H, Papa E, Gramatica P. QSAR prediction of estrogen activity for a large set of diverse chemicals under the guidance of OECD principles. Chem Res Toxicol 2006;19:1540-8 (Pubitemid 44863497)
31. Nicolotti O, Altomare C, Pellegrini-Calace M, Carotti A. Neuronal nicotinic acetylcholine receptor agonists: pharmacophores, evolutionary QSAR and 3D-QSAR models. Curr Top Med Chem 2004;4:335-60 (Pubitemid 38842573)
32. Selwood DL, Livingstone DJ, Comley JC, et al. Structure-activity relationships of antifilarial antimycin analogues: a multivariate pattern recognition study. J Med Chem 1990;33:136-42 (Pubitemid 20038183)
33. Rogers D, Hopfinger AJ. Application of genetic function approximation to quantitative structure-activity relationships and quantitative structure-property relationships. J Chem Inf Comput Sci 1994;34:854-66
34. Kubinyi H. Variable selection in QSAR studies. I. An evolutionary algorithm. Quant Struct Act Relat 1994;13:285-94
35. Nicolotti O, Carotti A. QSAR and QSPR studies of a highly structured physicochemical domain. J Chem Inf Model 2006;46:264-76 (Pubitemid 43282121)
36. Huuskonen J. Estimation of aqueous solubility for a diverse set of organic compounds based on molecular topology. J Chem Inf Comput Sci 2000;40:773-7
37. McElroy NR, Jurs PC. Prediction of aqueous solubility of heteroatom-containing organic compounds from molecular structure. J Chem Inf Comput Sci 2001;41:1237-47
38. Stockfisch TP. Partially unified multiple property recursive partitioning (PUMP-RP): a new method for predicting and understanding drug selectivity. J Chem Inf Comput Sci 2003;43:1608-13
39. Cruz-Monteagudo M, Borges F, Cordeiro MN. Desirability-based multiobjective optimization for global QSAR studies: application to the design of novel NSAIDs with improved analgesic, antiinflammatory, and ulcerogenic profiles. J Comput Chem 2008;29:2445-59
40. Derringer G, Suich R. Simultaneous optimization of several response variables. J Qual Technol 1980;12:214-19
41. Cruz-Monteagudo M, Borges F, Cordeiro MN, et al. Desirability-based methods of multiobjective optimization and ranking for global QSAR studies. Filtering safe and potent drug candidates from combinatorial libraries. J Comb Chem 2008;10:897-913
42. Machado A, Tejera E, Cruz-Monteagudo M, Rebelo I. Application of desirability-based multi (bi)-objective optimization in the design of selective arylpiperazine derivates for the 5-HT1A serotonin receptor. Eur J Med Chem 2009;44:5045-54
43. Rajamani R, Good AC. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development. Curr Opin Drug Discov Devel 2007;10:308-15 (Pubitemid 46804927)
44. Kroemer RT. Structure-based drug design: docking and scoring. Curr Protein Pept Sci 2007;8:312-28 (Pubitemid 47317039)
45. Janson S, Merkle D. A new multi-objective particle swarm optimization algorithm using clustering applied to automated docking. In: Blesa MJ, Blum C, Roli A, et al. editors, Hybrid Metaheuristics Second International Workshop, HM 2005, Barcelona, Spain, August 29-30, 2005, Proceedings. Springer-Verlag, Berlin, Germany; 2005. p. 128-41 (Pubitemid 41480525)
46. Fuhrmann J, Rurainski A, Lenhof HP, Neumann D. A new Lamarckian genetic algorithm for flexible ligand-receptor docking. J Comput Chem 2010;31:1911-18
47. Nicolotti O, Giangreco I, Miscioscia TF, Carotti A. Improving quantitative structure-activity relationships through multiobjective optimization. J Chem Inf Model 2009;49:2290-302
48. Nicolotti O, Miscioscia TF, Carotti A, et al. An integrated approach to ligand-and structure-based drug design: development and application to a series of serine protease inhibitors. J Chem Inf Model 2008;48:1211-26
49. Bohm M, Sturzebecher J, Klebe G. Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa. J Med Chem 1999;42:458-77 (Pubitemid 29085107)
50. Schneider G, Lee ML, Stahl M, Schneider P. De novo design of molecular architectures by evolutionary assembly of drug-derived building blocks. J Comput Aided Mol Des 2000;14:487-94 (Pubitemid 30386823)
51. Firth-Clark S, Todorov NP, Alberts IL, et al. Exhaustive de novo design of low-molecular-weight fragments against the ATP-binding site of DNA-gyrase. J Chem Inf Model 2006;46:1168-73 (Pubitemid 43999161)
52. Douguet D, Munier-Lehmann H, Labesse G, Pochet S. LEA3D: a computer-aided ligand design for structure-based drug design. J Med Chem 2005;48:2457-68 (Pubitemid 40516437)
53. Brown N, McKay B, Gilardoni F, Gasteiger J. A graph-based genetic algorithm and its application to the multiobjective evolution of median molecules. J Chem Inf Comput Sci 2004;44:1079-87
54. Brown N, McKay B, Gasteiger J. A novel workflow for the inverse QSPR problem using multiobjective optimization. J Comput Aided Mol Des 2006;20:333-41 (Pubitemid 44530546)
55. Lameijer EW, Kok JN, Back T, Ijerman AP. The molecule evoluator. An interactive evolutionary algorithm for the design of drug-like molecules. J Chem Inf Model 2006;46:545-52
56. Hajduk PJ. Puzzling through fragment-based drug design. Nat Chem Biol 2006;2:658-9 (Pubitemid 44764204)
57. Wyatt PG, Woodhead AJ, Berdini V, et al. Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. J Med Chem 2008;51:4986-99
58. Howard S, Berdini V, Boulstridge JA, et al. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 2009;52:379-88
59. Murray CW, Carr MG, Callaghan O, et al. Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. J Med Chem 2010;53:5942-55
60. Woodhead AJ, Angove H, Carr MG, et al. Discovery of (2,4-dihydroxy-5- isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl] methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem 2010;53:5956-69
61. Dey F, Caflisch A. Fragment-based de novo ligand design by multiobjective evolutionary optimization. J Chem Inf Model 2008;48:679-90 (Pubitemid 351535435)
62. Manoharan P, Vijayan RS, Ghoshal N. Rationalizing fragment based drug discovery for BACE1: insights from FB-QSAR, FB-QSSR, multi objective (MO-QSPR) and MIF studies. J Comput Aided Mol Des 2010;24:843-64
63. Nicolaou CA, Apostolakis J, Pattichis CS. De novo drug design using multiobjective evolutionary graphs. J Chem Inf Model 2009;49:295-307
64. Choe Y, Leonetti F, Greenbaum DC, et al. Substrate profiling of cysteine proteases using a combinatorial peptide library identifies functionally unique specificities. J Biol Chem 2006;281:12824-32 (Pubitemid 43855375)
65. Merrifield RB. Solid phase synthesis. Nobel lecture, 8 December 1984
66. Gillet VJ, Khatib W, Willett P, et al. Combinatorial library design using a multiobjective genetic algorithm. J Chem Inf Comput Sci 2002;42:375-85 (Pubitemid 35355312)
67. Pellegrino G, Leonetti F, Carotti A, et al. Solid phase synthesis of a molecular library of pyrimidines, pyrazoles, and isoxazoles with biological potential. Tetrahedron Lett 2010;51:1702-5
68. Gillet VJ, Nicolotti O. Evaluation of reactant-based and product-based approaches to the design of combinatorial libraries. Persp Drug Discov Des 2000;20:265-87
69. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001;46:3-26 (Pubitemid 33653411)
70. Gillet VJ, Willett P, Bradshaw J. Identification of biological activity profiles using substructural analysis and genetic algorithms. J Chem Inf Comput Sci 1998;38:165-79 (Pubitemid 128591234)
71. Gillet VJ, Willett P, Bradshaw J, Green DVS. Selecting combinatorial libraries to optimize diversity and physical properties. J Chem Inf Comput Sci 1999;39:169-77 (Pubitemid 129676573)
72. Zheng W, Hung ST, Saunders JT, Seibel GL. PICCOLO: a tool for combinatorial library design via multicriterion optimization. Pac Symp Biocomput 2000;5:585-96
73. Rassokhin DN, Agrafiotis DK. Kolmogorov-Smirnov statistic and its application in library design. J Mol Graph Model 2000;18:368-82
74. Agrafiotis DK. Multiobjective optimization of combinatorial libraries. Mol Divers 2000;5:209-30 (Pubitemid 36076936)
75. Le Bailly de Tilleghem C, Beck B, Boulanger B, Govaerts B. A fast exchange algorithm for designing focused libraries in lead optimization. J Chem Inf Model 2005;45:758-67 (Pubitemid 40795179)
76. Gillet VJ, Khatib W, Willett P, et al. Combinatorial library design using a multiobjective genetic algorithm. J Chem Inf Comput Sci 2002;42:375-85 (Pubitemid 35355312)
77. Gillet VJ, Willet P, Fleming PJ, Green DVS. Designing focused libraries using MoSELECT. J Mol Graph Model 2002;20:491-8 (Pubitemid 34312064)
78. Fonseca CM, Fleming PJ. Multiobjective optimization and multiple constraint handling with evolutionary algorithms. I: a unified formulation. IEEE Trans Syst Man Cybernet 1998;28:26-37 (Pubitemid 128748052)
79. Wright T, Gillet VJ, Green DVS, Pickett SD. Optimizing the size and configuration of combinatorial libraries. J Chem Inf Comput Sci 2003;43:381-90
80. Soltanshahi F, Mansley TE, Choi S, Clark RD. Balancing focused combinatorial libraries based on multiple GPCR ligands. J Comput Aided Mol Des 2006;20:529-38 (Pubitemid 44823889)
81. Hohm T, Limbourg P, Hoffman D. A multiobjective evolutionary method for the design of peptidic mimotopes. J Comput Biol 2006;13:113-25 (Pubitemid 43376493)
82. Fischer JR, Lessel U, Rarey M. LoFT: similarity-driven multiobjective focused library design. J Chem Inf Model 2010;50:1-21